JP Morgan downgraded Genmab from Overweight to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/1/2025 | Mkt Perform → Underperform | Bernstein | |
| 3/11/2025 | Mkt Perform → Outperform | William Blair | |
| 2/13/2025 | $27.00 | Market Perform → Outperform | Leerink Partners |
| 10/8/2024 | Buy | Redburn Atlantic | |
| 9/4/2024 | $31.00 | Equal-Weight | Morgan Stanley |
| 8/20/2024 | Overweight → Neutral | JP Morgan | |
| 7/15/2024 | Sector Perform → Outperform | RBC Capital Mkts | |
| 2/23/2024 | $46.00 → $48.00 | Market Perform → Outperform | BMO Capital Markets |
6-K - GENMAB A/S (0001434265) (Filer)
6-K - GENMAB A/S (0001434265) (Filer)
6-K - GENMAB A/S (0001434265) (Filer)
Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (NASDAQ:GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 16 to June 20, 2025: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 2,080,711 2,706,417,889.19June 16, 2025XCSE1001,477.73147,772.50 BCXE0 AQEU0 TQEX0 Total100 147,772.50June 17, 2025XCSE1001,
Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (NASDAQ:GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 27,396 shares at DKK 1,025.00,2,790 shares at DKK 1,050.00, 150 shares at DKK 1,147.50,1,557 shares at DKK 1,161.00, and224 shares at DKK 1,334.50. Proceeds to the company are approximately DKK 33.3 million. The increase corresponds to approximately 0.05% of the company's share capital. The new shares are ord
Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (NASDAQ:GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (NASDAQ:GMAB) by managerial employees and their closely associated persons. The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company's managerial employees and their closely associated persons. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team
Bernstein downgraded Genmab from Mkt Perform to Underperform
William Blair upgraded Genmab from Mkt Perform to Outperform
Leerink Partners upgraded Genmab from Market Perform to Outperform and set a new price target of $27.00
Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera
Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (NASDAQ:GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 27,396 shares at DKK 1,025.00,2,790 shares at DKK 1,050.00, 150 shares at DKK 1,147.50,1,557 shares at DKK 1,161.00, and224 shares at DKK 1,334.50. Proceeds to the company are approximately DKK 33.3 million. The increase corresponds to approximately 0.05% of the company's share capital. The new shares are ord
Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38 Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a
Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT COPENHAGEN, Denmark; March 10, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising
SC 13G/A - GENMAB A/S (0001434265) (Subject)
SC 13G/A - GENMAB A/S (0001434265) (Subject)
SC 13G - GENMAB A/S (0001434265) (Subject)